News & Events

In the RSNN afternoon session of the FIGON Dutch Medicines Days, future evidence generation strategies were discussed.

Last week, the Medicines Evaluation Board (MEB) launched its 6th edition of the Regulatory Science Magazine.

In the RSNN morning session of the FIGON Dutch Medicines Days speakers from different perspectives presented their views on the challenges that come with the development of innovative oncology treatments.

To advance its engagement with regulatory science, the EMA gathered insights from stakeholders during a workshop on October 24.

Regulatory science was an important topic during the Partnerships MeetUp on November 1st.

During the FIGON Dutch Medicines Days on October 1-2, the RSNN organized two regulatory science sessions around novel cancer treatments and the associated regulatory challenges. We look back at engaging presentations and discussions with a large, varied group of stakeholders. 

The fifth RSNN newsletter is out now! In this edition we report on the RSNN Workshop ‘What’s in, What’s out, What’s relevant? – Towards a sensible label’ held on June 20th 2018, and announce upcoming meetings.

Earlier this month, Nature Reviews Drug Discovery (NRDD) published an article about Medicines Adaptive Pathways to Patients' (MAPPs). MAPPs seek to foster access to novel beneficial treatments for the right patient groups at the earliest appropriate time in the product life-span, in a sustainable fashion.

In this edition, we report on the Regulatory Science session on disease interception (BOX 3) held at the FIGON Dutch Medicines Days on October 2, 2017. In the morning, three excellent academic speakers provided examples of disease interception opportunities. In the afternoon, two speakers shared the industry and regulatory positions on disease interception.

In this edition you will find a first impression of the RSNN Workshop ‘Beyond the current clinical endpoints’ held on July 6, 2017, and announcements of upcoming meetings. We also present the standing executive - and steering committee of the RSNN.

This edition reports on Regulatory Science sessions held at the FIGON Dutch Medicines Days on October 3 2016, which focused on the regulatory aspects of orphan drug development and the search for new methods of scientific research in small patient groups.

This is the first Newsletter of the Regulatory Science Network Netherlands (RSNN). The RSNN was founded October last year during the Dutch Medicines Days organized by FIGON, the integrative platform for innovative drug research in the Netherlands.